#DARE Daré Bioscience 2024 Q3 Earnings: Daré Bioscience reported a better-than-expected EPS and significant progress in its women's health development programs in Q3 2024.
- Revenue: $41,691
- Net Loss: $4.7 million
- EPS: -$0.55 vs. forecast -$0.60 (2 analysts)
- Cash and Equivalents: $11.2 million
- Foundation Grant: $10.7M for Ovaprene
- Equity Line: $15M with Lincoln Park
- Royalty Financing: $22M secured
"We continue to execute on our mission to accelerate development of and bring to market innovative treatments that women want and need by advancing our late-stage candidates – all of which represent a first-in-category opportunity – as we seek to deliver value for all Daré stakeholders." - Sabrina Martucci Johnson, President and CEO of Daré Bioscience
If you enjoyed this video, please like, subscribe, and hit the notification bell to stay updated with our latest stock analysis and market insights. Leave a comment below with your thoughts on the video, and any other stocks you'd like us to cover.
*Check out our latest videos on more earnings:*
- #VNRX VolitionRx 2024 Q3 Earnings: [ Ссылка ]
- #AREC American Resources 2024 Q3 Earnings: [ Ссылка ]
- #SRTS Sensus Healthcare 2024 Q3 Earnings: [ Ссылка ]
- #GCTS GCT Semiconductor Holding 2024 Q3 Earnings: [ Ссылка ]
- #INO INOVIO 2024 Q3 Earnings: [ Ссылка ]
